Skip to main content
SpringerLink
Log in

Intranasal Medications for the Treatment of Migraine and Cluster Headache

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Intranasal medications for the treatment of headache have recently received increased attention. This paper reviews intranasal formulations of a variety of available medications (dihydroergotamine mesylate [dihydroergotamine mesilate], sumatriptan, zolmitriptan, butorphanol, capsaicin and lidocaine [lignocaine]) and one experimental medication (civamide, a cis-isomer of capsaicin) for the treatment of migraine and cluster headache.

Although the efficacy of intranasal agents varies with the product used, intranasal delivery may be both convenient and more effective than other modes of drug delivery for a variety of reasons: (i) intranasal administration bypasses small bowel gastrointestinal tract absorption, which is often significantly delayed during the acute phase of a migraine attack; (ii) nauseated patients may prefer non-oral formulations as they decrease the chance of vomiting and are more rapidly effective; (iii) intranasal administration causes no pain or injection site reaction and is easier and more convenient to administer than injection or suppository and so may be used earlier in a migraine attack, resulting in better efficacy; (iv) intranasal medication produces the same number or fewer adverse events than injections; and (v) intranasal formulations offer a more rapid onset of action than oral medications, for some of the above reasons and, as such, may be more useful in patients with cluster headache, although this needs to be verified. However, it is important to emphasise that a preference study showed that most patients prefer oral tablets to an intranasal formulation. Also, some nasal preparations have significant adverse effects or are not well absorbed and therefore do not work consistently; others are more challenging to administer as a result of their delivery apparatus. Nevertheless, it is our opinion that nasal preparations increase therapeutic options and may result in faster response times and better efficacy than oral formulations and better patient satisfaction than injectable preparations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646–57

    Article  PubMed  CAS  Google Scholar 

  2. Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie IK, editor. Epidemiology of pain. Seattle: IASP Press, 1999: 159–70

    Google Scholar 

  3. Goadsby PJ. Pathophysiology of headache. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolffs headache and other head pain. 7th ed. New York: Oxford University Press, 2001: 57–72

    Google Scholar 

  4. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin 1990; 8: 801–15

    PubMed  CAS  Google Scholar 

  5. Blumenthal HJ, Rapoport AM. The clinical spectrum of migraine. In: Mathew NT, editor. The medical clinics of North America. Vol. 85. Philadelphia (PA): WB Saunders, 2001: 897–909

    Google Scholar 

  6. Kudrow L. Epidemiology of cluster headache. In: Kudrow L, editor. Cluster headache: mechanisms and management. New York: Oxford University Press, 1980: 100–50

    Google Scholar 

  7. Ekbom K, Ahlborg B, Schéle R. Prevalence of migraine and cluster headache in Swedish men of 18. Headache 1978; 18: 9–19

    Article  PubMed  CAS  Google Scholar 

  8. Tonon C, Guttmann S, Volpini M, et al. Prevalence and incidence of cluster headache in the Republic of San Marino. Neurology 2002; 58: 1407–9

    Article  PubMed  CAS  Google Scholar 

  9. Ad Hoc Committee on Classification of Headache. JAMA 1962; 179: 717–8

  10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8Suppl. 7: 9–96

    Google Scholar 

  11. Rapoport AM, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs 1997; 7: 37–46

    Article  Google Scholar 

  12. Tfelt-Hansen P, Saxena PR, Ferrari MD. Ergot alkaloids. In: Wolf FA, editor. Handbook of clinical neurology. Vol. 21. Amsterdam: Elsevier, 1995: 61–78

    Google Scholar 

  13. Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 399–409

    Google Scholar 

  14. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatr 1938; 39: 737–63

    Article  CAS  Google Scholar 

  15. Tfelt-Hansen P, Eickhoff JH, Olesen J. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve. Acta Pharmacol Toxicol (Copenh) 1980; 47: 151–6

    Article  CAS  Google Scholar 

  16. Stevens AA. Modern materia medica and therapeutics. Philadelphia (PA): WB Saunders Co, 1907

    Google Scholar 

  17. Müller-Schweinitzer E. Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol. 1984; 26: 699–705

    Article  PubMed  Google Scholar 

  18. Müller-Schweinitzer E. Weidmann H. Basic Pharmacological properties. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Berlin: Springer-Verlag, 1978: 87–232

    Chapter  Google Scholar 

  19. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997; 37Suppl. 1: 15–25

    PubMed  Google Scholar 

  20. Tfelt-Hansen P. Clinical pharmacology of ergotamine: an overview. In: Diener H-C, Wilkinson M, editors. Drug-induced headache. Berlin: Springer-Verlags, 1988: 105–116

    Chapter  Google Scholar 

  21. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet 1985; 10: 334–52

    Article  PubMed  CAS  Google Scholar 

  22. Little PJ, Jennings GL, Skews H, et al. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol 1982; 13: 785–90

    Article  PubMed  CAS  Google Scholar 

  23. Data on file, Sandoz Pharmaceuticals Corporation, 2003

  24. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994; 44: 447–53

    Article  PubMed  CAS  Google Scholar 

  25. Mathew NT. Dosing and administration of ergotamine tartrate and dihydroergotamine. Headache 1997; 37Suppl. 1: 26–32

    Google Scholar 

  26. Berde B, Stürmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Berlin: Springer-Verlag, 1978: 1–28

    Chapter  Google Scholar 

  27. Chu D, Owen DAA, Stürmer E. Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad Med J 1976; 52Suppl. 1: 32–6

    CAS  Google Scholar 

  28. Winner P, Dalessio D, Mathew N, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache 1993; 33: 471–5

    Article  PubMed  CAS  Google Scholar 

  29. Winner P, Ricalde O, LeForce B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180–4

    Article  PubMed  CAS  Google Scholar 

  30. Belgrade MJ, Ling LJ, Schleevogt MB, et al. Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache. Neurology 1989; 39: 590–2

    Article  PubMed  CAS  Google Scholar 

  31. Weisz MA, EI-Raheb M, Blumenthal HJ. Home administration of intramuscular dihydroergotamine mesilate for the treatment of acute migraine headache. Headache 1994; 34: 371–3

    Article  PubMed  CAS  Google Scholar 

  32. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994; 44: 447–53

    Article  PubMed  CAS  Google Scholar 

  33. Scott AK. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches. Clin Neuropharmacol 1992; 15: 289–92

    Article  PubMed  CAS  Google Scholar 

  34. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994; 44: 447–53

    Article  PubMed  CAS  Google Scholar 

  35. The Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995; 35: 177–85

    Article  Google Scholar 

  36. Gallagher RM. Dihydroergotamine Working Group. Acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol 1996; 53: 1285–91

    CAS  Google Scholar 

  37. Boureau F, Kappos L, Schoenen J, et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract. 2000 Jun; 54(5): 281–6

    PubMed  CAS  Google Scholar 

  38. Tepper SJ, Rapoport AM. The triptans: a summary. CNS Drugs 1999; 12: 403–17

    Article  CAS  Google Scholar 

  39. Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 183–9

    Google Scholar 

  40. Halpern MT, Lipton RB, Cady RK, et al. Cost-effectiveness of sumatriptan therapy: early vs delayed treatment [abstract]. Cephalalgia 2001; 21: 336

    Article  Google Scholar 

  41. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291–4

    Article  PubMed  CAS  Google Scholar 

  42. Sheftell FD, Bigal ME, Tepper SJ, et al. Sumatriptan: a decade of use and experience in the treatement of migraine. Expert Rev Neurotherapeutics 2004; 4(2): 199–209

    Article  CAS  Google Scholar 

  43. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology. 1997 Nov; 49(5): 1225–30

    Article  PubMed  CAS  Google Scholar 

  44. Moore KH, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997 Jun; 17(4): 541–50

    Article  PubMed  CAS  Google Scholar 

  45. Salonen R, Ashford E, Dahlof C. Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neurol 1994; 241: 463–9

    CAS  Google Scholar 

  46. The Finnish Sumatriptan Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 332–8

    Article  Google Scholar 

  47. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997; 49: 1225–30

    Article  PubMed  CAS  Google Scholar 

  48. Peikert A, Becker WJ, Ashford EA, et al. Sumatriptan nasal spray: a dose ranging study in the acute treatment of migraine. Eur J Neurol 1999; 6: 43–9

    Article  PubMed  CAS  Google Scholar 

  49. Diamond S, Elkind A, Jackson RT, et al. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 1988; 7: 234–40

    Article  Google Scholar 

  50. Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003; 17(9): 653–67

    Article  PubMed  CAS  Google Scholar 

  51. Dowson AJ, Charlesworth BR, Purdy A, et al. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 2003; 17(11): 839–51

    Article  PubMed  CAS  Google Scholar 

  52. Ashford E, Salonen R, Saiers J, et al. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 1998 Jun; 18(5): 273–7

    Article  PubMed  CAS  Google Scholar 

  53. Geraud G, Valette C. Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients. Rev Neurol 2000; 156(6–7): 646–53

    PubMed  CAS  Google Scholar 

  54. Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000 ov; 106(5): 989–97

    Article  PubMed  CAS  Google Scholar 

  55. Rothner AD, Winner P, Nett R, et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin Ther 2000; 22(12): 1533–46

    Article  PubMed  CAS  Google Scholar 

  56. Carpay JA, Linssen WH, Koehler PJ, et al. Efficacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study. Headache 2003; 43(4): 395–9

    Article  PubMed  CAS  Google Scholar 

  57. Hardebo JE, Dahlof C. Sumatriptan nasal spray (20 mg/dose) in the acute treatment of cluster headache. Cephalalgia 1998 Sep; 18(7): 487–9

    Article  PubMed  CAS  Google Scholar 

  58. Van Vliet JA, Bahra A, Martin V, et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003 Feb 25; 60(4): 630–3

    Article  PubMed  Google Scholar 

  59. Torres G. Zolmitriptan offers doctors and patient choices for effective treatment of migraine. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York (NY): Oxford University Press, 2001: 190–8

    Google Scholar 

  60. Sorensen J, Bergstrom M, Antoni G, et al. Distribution of 11C-zolmitriptan nasal spray assessed by positron emission tomography (PET). Eur J Neurol 2000; 7 Suppl. 3: 82

    Google Scholar 

  61. Abu-Shakra S, Zingmark PH, Yates R, et al. True nasopharyngeal absorption of zolmitriptan following administration of zolmitriptan nasal spray [abstract]. Headache 2002; 42: 389

    Article  Google Scholar 

  62. Nairm K, Kemp JV, Dane AL, et al. Evaluation of the effect of xylometazine on the absorption of zolmitriptan nasal spray. Clin Drug Invest 2002; 22: 703–7

    Article  Google Scholar 

  63. Rapoport AM, Charlesworth B, Freitag F, et al. Efficacy of zolmitriptan at early time points in the acute treatment of migraine [abstract]. Headache 2003; 43: 527

    Article  Google Scholar 

  64. Dodick D, Brandes J, Elkind A, et al. Early efficacy and excellent tolerability of zolmitriptan nasal spray in acute migraine. Neurology 2004; 62 Suppl. 5: 181

    Google Scholar 

  65. Gawel M, Aschoff J, Lee J, et al. Zolmitriptan nasal spray is highly efficacious, very fast acting and produces sustained relief in the treatment of acute migraine in a real life setting: results from phase I of the REALIZE study [abstract]. Ann Neurology 2003; 54 Suppl. 7: 32

    Google Scholar 

  66. Matchar DB, Young DB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache pharmacological management of acute attacks [online]. Available from URL: http://www.aan.com/professionals/practice/pdfs/gl0087.pdf [Accessed 203 Jul 10]

  67. Fisher MA, Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology 1997 May; 48(5): 1156–60

    Article  PubMed  CAS  Google Scholar 

  68. Gillis JC, Benfield P, Goa KL. Transnasal butorphanol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 1995; 50(1): 157–75

    Article  PubMed  CAS  Google Scholar 

  69. Belgrade MJ, Ling LJ, Schleevogt MB, et al. Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache. Neurology 1989; 39(4): 590–2

    Article  PubMed  CAS  Google Scholar 

  70. Melanson SW, Morse JW, Pronchik DJ, et al. Transnasal butorphanol in the emergency department management of migraine headache. Am J Emerg Med 1997; 15(1): 57–61

    Article  PubMed  CAS  Google Scholar 

  71. Srinivas NR, Shyu WC, Upmalis D, et al. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate. J Clin Pharmacol 1995; 35(4): 432–7

    PubMed  CAS  Google Scholar 

  72. Fitzgerald M. Capsaicin and sensory neurons: a review. Pain 1983; 15: 109–30

    Article  PubMed  CAS  Google Scholar 

  73. Diamond S, Freitag F, Phillips SB, et al. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia. 2000 Jul; 20(6): 597–602

    Article  PubMed  CAS  Google Scholar 

  74. Sicuteri F, Fusco BM, Marabini S, et al. Beneficial effect of capsaicin application to the nasal mucosa in cluster headache. Clin J Pain 1989; 5(1): 49–53

    Article  PubMed  CAS  Google Scholar 

  75. Marks DR, Rapoport A, Padla D,et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 1993; 13: 114–6

    Article  PubMed  CAS  Google Scholar 

  76. Saper JR, Klapper J, Mathew NT, et al. Intranasal civamide for the treatment of episodic cluster headaches. Arch Neurol 2002; 59(6): 990–4

    Article  PubMed  Google Scholar 

  77. Kudrow L, Kudrow DB, Sandweiss JH. Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings. Headache 1995 Feb; 35(2): 79–82

    Article  PubMed  CAS  Google Scholar 

  78. Maizels M, Scott B, Cohen W, et al. Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA 1996 Jul 24–31; 276(4): 319–21

    Article  PubMed  CAS  Google Scholar 

  79. Blanda M, Rench T, Gerson LW, et al. Intranasal lidocaine for the treatment of migraine headache: a randomized, controlled trial. Acad Emerg Med 2001 Apr; 8(4): 337–42

    Article  PubMed  CAS  Google Scholar 

  80. Robbins L. Intranasal lidocaine for cluster headache. Headache 1995 Feb; 35(2): 83–4

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have received grant support and research funding in the past from GlaxoSmithKline, AstraZeneca, Merck, Abbott, VCB and others. The authors have provided no information on sources of funding directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Columbia University College of Physicians & Surgeons, New York, New York, USA

    Alan M. Rapoport

  2. The New England Center for Headache, P.C. 778 Long Ridge Road, Stamford, Connecticut, 06902-1251, USA

    Alan M. Rapoport, Marcelo E. Bigal, Stewart J. Tepper & Fred D. Sheftell

  3. Department of Neurology, Albert Einstein College of Medicine, New York, New York, USA

    Marcelo E. Bigal

  4. Yale University School of Medicine, New Haven, Connecticut, USA

    Stewart J. Tepper

  5. New York Medical College, New York, New York, USA

    Fred D. Sheftell

Authors
  1. Alan M. Rapoport
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcelo E. Bigal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stewart J. Tepper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fred D. Sheftell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan M. Rapoport.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rapoport, A.M., Bigal, M.E., Tepper, S.J. et al. Intranasal Medications for the Treatment of Migraine and Cluster Headache. CNS Drugs 18, 671–685 (2004). https://doi.org/10.2165/00023210-200418100-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200418100-00004

Keywords

Search

Navigation